Welcome, Guest

TOPIC:

Zepatier - PBAC yes for GT1 but no for GT3 7 years 3 months ago #20968

DrJames
Topic Author
Offline
Platinum Member
Posts: 1980
Karma: 111
Thank you received: 7263

The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees]

YMMV

The following user(s) said Thank You: pat1, Gaj, Hieupham, re_roll, Peach

Zepatier - PBAC yes for GT1 but no for GT3 7 years 3 months ago #20974

pat1
Offline
Platinum Member
Posts: 340
Karma: 15
Thank you received: 977

That is wonderful news for genotypes 4 and 6 including G1's but it seems so very unfair for those with G3. Where is the dislike tab?

gt 1a VL 6m
F2/3 FibroScan - 9KPa in 2011 and 7KPa in 2015
sof/dac 10 December for 12 weeks
pre tx alt 85 ast 51
4 wk alt 34 ast 31 UND <35
8 wk alt 29 ast 32 UND <15
12wk alt 25 ast 25 EOT 3.3.16
SVR24 UND KPa5.3 F0 in normal range
I am well
.forever grateful to fixhepc

The following user(s) said Thank You: DrJames, Paul-Jarman-facebook, Gaj, re_roll

Zepatier - PBAC yes for GT1 but no for GT3 7 years 2 months ago #21260

Paul-Jarman-facebook Offline Moderator The gypsy woman told my mother Before I was born Posts: 383 Karma: 9 Thank you received: 659	Maybe it's possible that Zepatier could interfere with the PBAC's deal with Gilead and funding caps given that G3 is more prevelant here. Two time relapser. SVR 4 achieved 12/16 at last SVR 12 achieved 22/02/2017 The Bastard has been defeated GT 3 - about 28 yrs with HCV The following user(s) said Thank You: Donna